Related Experiment Video

Updated: Jun 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Advances in breast cancer treatment: the emerging role of ixabepilone

Debra K Frye1

  • 1Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. dfrye@mdanderson.org

Expert Review of Anticancer Therapy
|December 18, 2009
PubMed

Insights

Ixabepilone is effective for metastatic breast cancer resistant to other treatments. Clinical trials show it improves progression-free survival, especially in combination therapy, with a manageable safety profile.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Taxanes and anthracyclines are standard breast cancer treatments but resistance is common.
  • Ixabepilone, an epothilone, offers an alternative for patients with resistant metastatic breast cancer.

Purpose of the Study:

  • To review updated clinical data on ixabepilone in breast cancer treatment.
  • To discuss administration and side-effect management of ixabepilone.

Main Methods:

  • Review of clinical trial data involving over 2000 patients treated with ixabepilone.
  • Analysis of efficacy in minimally and heavily pretreated patient populations.
  • Evaluation of combination therapy outcomes, specifically ixabepilone/capecitabine.

Main Results:

  • Ixabepilone demonstrates efficacy in overcoming chemotherapy resistance.
  • Combination therapy with ixabepilone and capecitabine showed a progression-free survival advantage over capecitabine alone.
  • Ixabepilone has a manageable safety profile across diverse patient groups.

Conclusions:

  • Ixabepilone is a valuable therapeutic option for metastatic breast cancer, including resistant cases.
  • Ixabepilone offers benefits in specific hard-to-treat patient subgroups.
  • Further understanding of ixabepilone administration and toxicity is crucial for optimal patient care.

More Related Videos

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...